Oculis plans a late-2026 filing to study privosegtor as a potential neuroprotective treatment for acute MS relapse.

The US Food and Drug Administration (FDA) has granted breakthrough device designation to the Elecsys Neurofilament Light Chain (NfL) test for multiple sclerosis (MS). Made by Roche, the test is ...

The test that was developed using an existing diagnostic procedure as its basis and has the potential to be applied in clinical trials that target the Epstein Barr Virus. MS is a chronic neurological ...

In an editorial in the journal Frontiers in Neurology, two leading multiple sclerosis (MS) experts are advocating for genetic testing to identify MS patients who are at higher risk of developing a ...

No single test can confirm multiple sclerosis (MS) or discount it. Instead, doctors test for MS by ruling out other possible diagnoses and then looking for signs of MS-related damage. MS is an ...

Share on Pinterest Scientists are trying to find blood biomarkers that may help predict the course of disease in MS. Betsie Van der Meer/Getty Images As of 2020, about 2.8 million people globally have ...

MENLO PARK, Calif.--(BUSINESS WIRE)--Octave Bioscience, Inc., a commercial-stage precision care company pioneering biomarker-driven solutions for multiple sclerosis (MS) and other neurodegenerative ...

A recent study found patients with multiple sclerosis (MS) experienced depressive and anxiety symptoms during the COVID-19 pandemic prior to vaccine rollout, especially among those who tested positive ...

A blood test might predict when multiple sclerosis patients are about to suffer a relapse in their symptoms, a new study says. Blood levels of a protein called neurofilament light chain rise ...